Evaxion launches improved AI-Immunology™ platform for vaccine antigen prediction
The new version 5.0 of the AI model EDEN™ features a novel toxin antigen predictor, is trained on an expanded...
Pharmaceutical
Aligos Therapeutics Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH
ALG-055009 dose groups met the primary endpoint with statistically significant reductions in liver fat at Week 12 as measured by...
Cidara Therapeutics Strengthens its Scientific Advisory Board with Infectious Disease Experts
SAN DIEGO, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform...
Arcutis Announces Publication of ZORYVE® (roflumilast) Cream 0.15% Pivotal Results from Phase 3 INTEGUMENT-1 and -2 Trials in Mild to Moderate Atopic Dermatitis in Journal of American Medical Association Dermatology
ZORYVE® (roflumilast) cream 0.15% improved atopic dermatitis (AD) across multiple efficacy endpoints while demonstrating favorable safety and tolerabilityAcross both studies,...
CorMedix Inc. Announces New Commercial Agreement
BERKELEY HEIGHTS, N.J., Sept. 19, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing therapeutic...
Psyence Biomed Enters into Agreement to Acquire Stake in PsyLabs
PsyLabs develops and produces certified pharmaceutical-grade natural psychedelics for applications in mental health and well-beingNEW YORK, Sept. 19, 2024 (GLOBE...
Lifecore Biomedical Announces High-Speed, Multi-Purpose 5-Head Isolator Filler is GMP-Ready and Operational
Installation and Qualification Successfully Completed for Closed-System Filler for Pre-Filled Syringes, Vials, and Cartridges Offers State-of-the-Art Speed and Aseptic Isolation...
Tonix Pharmaceuticals Announces Issuance of U.S. Patent by the United States Patent and Trademark Office Covering the Intranasal Delivery of FDA-Approved Tosymra® to Treat Migraines
New patent expected to expire in 2030 Tosymra® (sumatriptan nasal spray) 10mg is indicated and marketed for the acute treatment...
BioXcel Therapeutics Announces Clinical Prioritization and Update on BXCL501 Late-Stage Programs for Agitation
Recently initiated SERENITY At-Home pivotal Phase 3 trial for agitation associated with bipolar disorders or schizophrenia Submitted protocol to FDA...
Achilles Therapeutics Announces Strategic Update
–Achilles to discontinue development of TIL-based cNeT therapy– –Cash position of $95.1 million as of June 30, 2024– –BofA Securities...
Vivos Therapeutics Announces Pricing of $4.3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
LITTLETON, Colo., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device...
Tiziana Life Sciences Announces $4 Million Grant Awarded by National Institutes of Health to Study Anti-CD3 in Alzheimer’s Disease
NEW YORK, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology...
Dr. Paulo Fontoura, MD, PhD, joins STALICLA as Chief Scientific and Clinical Development Advisor
Press Release Dr. Paulo Fontoura, MD, PhD, joins STALICLA as Chief Scientific and Clinical Development Advisor Geneva, Switzerland – September...
ITM to Present at Upcoming Radiopharmaceutical Investor Conferences in New York City
Garching / Munich, September 19, 2024 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced...
Basilea enters into agreement with BARDA to develop novel antifungals and antibacterials and receives initial funding
Initial funding of USD 29 million to support development of Basilea’s clinical stage first-in-class antifungals, fosmanogepix and BAL2062Multi-year Other Transaction...
U.S. grants Vidac Pharma patent offering broad protection of mode of action underlying its oncology drug candidates
London (UK), September 19 2024 – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical...
Positive phase III results show Xofluza significantly reduces the transmission of influenza viruses
Data from the CENTERSTONE study shows single-dose Xofluza reduces transmission of influenza from an infected person to household membersThis is...
Addex Provisional 2024 Half-Year and Second Quarter Result increased from a Net loss to a Net Profit
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 19, 2024 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage...
Cambrex Announces New Liquid-Phase Peptide Synthesis Manufacturing Technology
EAST RUTHERFORD, N.J., Sept. 19, 2024 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced...
TFS HealthScience Unveils Mission to Empower Partners and Enrich Lives Worldwide
New messaging reflects TFS's commitment to patient-centered clinical research and global partnerships LUND, Sweden, Sept. 19, 2024 /PRNewswire/ -- TFS HealthScience...